What top creators are saying about BioNTech SE(BNTX)
A German biotechnology company that partnered with Pfizer to develop an mRNA-based COVID-19 vaccine.
4 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Not enough scored insights about BioNTech SE in the last 30 days yet.
Top creators covering BioNTech SE (BNTX)
The 4 sources with the most insights about BioNTech SE on Kazuha.
Latest insights about BioNTech SE (BNTX)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Saturday, May 9, 2026
High beta winner; offers massive upside tied to specific catalysts, requiring strict exit timing.
Friday, February 13, 2026
As a partner with Pfizer, the company faces similar long-term reputational risks and potential legal challenges regarding its COVID-19 vaccine, with declining public trust potentially affecting future mRNA products.
Thursday, September 11, 2025
There is a strong long-term bullish case for companies at the forefront of mRNA research, like BioNTech, given the technology's revolutionary potential in high-value areas like oncology, though investors should monitor political risks related to research funding.
Friday, September 5, 2025
The company is exposed to the same bearish factors as its partner Pfizer, including the cancellation of a $500 million government contract and policy changes expected to significantly decrease demand for COVID-19 vaccines.
Saturday, May 9, 2026
High beta winner; offers massive upside tied to specific catalysts, requiring strict exit timing.
Friday, February 13, 2026
As a partner with Pfizer, the company faces similar long-term reputational risks and potential legal challenges regarding its COVID-19 vaccine, with declining public trust potentially affecting future mRNA products.
Thursday, September 11, 2025
There is a strong long-term bullish case for companies at the forefront of mRNA research, like BioNTech, given the technology's revolutionary potential in high-value areas like oncology, though investors should monitor political risks related to research funding.
Friday, September 5, 2025
The company is exposed to the same bearish factors as its partner Pfizer, including the cancellation of a $500 million government contract and policy changes expected to significantly decrease demand for COVID-19 vaccines.
Discussed alongside BioNTech SE (BNTX)
Other assets that creators frequently mention in the same content as BioNTech SE.
Frequently asked
Which podcasters and creators cover BioNTech SE (BNTX) the most?
The most active sources covering BioNTech SE (BNTX) on Kazuha are @theprofgpod, @cryptobantergroup, The New York Times, Joe Rogan. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about BioNTech SE (BNTX) are on Kazuha?
Kazuha has indexed 4 AI-extracted insights about BioNTech SE (BNTX) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside BioNTech SE (BNTX)?
Creators covering BioNTech SE (BNTX) most frequently also discuss MRNA, PFE, MAR, ZM, PTON. See the "Discussed alongside" section above for full asset pages.